More importantly, it is necessary to track dynamic changes in plasma Aβ and tau protein levels, as core biomarkers of AD, and explore the potential mechanism underlying PF4-driven molecular changes and cognitive improvement when PF4 is administered to the AD spectrum population. Here, MAPT is linked to Alzheimer disease.